Home » Stocks » SGTX

Sigilon Therapeutics, Inc. (SGTX)

Stock Price: $34.97 USD -0.49 (-1.38%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
Market Cap 1.08B
Revenue (ttm) 15.59M
Net Income (ttm) -33.70M
Shares Out 30.19M
EPS (ttm) -1.12
PE Ratio n/a
Forward PE 16.75
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $34.97
Previous Close $35.46
Change ($) -0.49
Change (%) -1.38%
Day's Open 35.89
Day's Range 33.38 - 36.32
Day's Volume 89,002
52-Week Range 27.60 - 48.03

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 6 days ago

CAMBRIDGE, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its S...

GlobeNewsWire - 1 month ago

Company plans to initiate a Phase 1/2 trial of SIG-005 in patients with mucopolysaccharidosis type I (MPS-1) in the second half of 2021 Company plans to initiate a Phase 1/2 trial of SIG-005 i...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (Nasdaq: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its S...

GlobeNewswire - 1 month ago

CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for...

TheStreet - 2 months ago

Cambridge, Massachusetts-based Sigilon was founded to develop its Shielded Living Therapeutics platform which uses advanced techniques to create therapeutic molecules for the treatment of rare...

Seeking Alpha - 2 months ago

Sigilon Therapeutics (SGTX) has filed a prospectus for a $100M IPO. The Cambridge, MA-based biotech develops cell therapies based on its Shielded Living Therapeutics (SLTx) platform that combi...

NASDAQ - 2 months ago

Sigilon Therapeutics, a clinical stage biotech developing molecular therapeutics for chronic diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

SEC - 2 months ago

Sigilon Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

About SGTX

Sigilon Therapeutics, a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc... [Read more...]

Industry
Biotechnology
IPO Date
Dec 4, 2020
CEO
Rogerio Vivaldi Coelho
Employees
96
Stock Exchange
NASDAQ
Ticker Symbol
SGTX
Full Company Profile

Financial Performance

In 2019, SGTX's revenue was $14.16 million, an increase of 205.26% compared to the previous year's $4.64 million. Losses were -$43.93 million, 92.9% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SGTX stock is "Buy." The 12-month stock price forecast is 53.75, which is an increase of 53.70% from the latest price.

Price Target
$53.75
(53.70% upside)
Analyst Consensus: Buy